DocWire News recently spoke with Allen Davidoff, Ph.D., the CEO of XORTX Therapeutics (pronounced Zor-tex).
XORTX is developing novel therapies for progressive kidney disease. The company is planning to launch a Phase 3 study for its lead candidate, oxypurinol, in patients with the rare disease Autosomal Dominant Polycystic Kidney Disease (ADPKD), with plans to expand to diabetic nephropathy (kidney failure in diabetes patients) and more.
This is on the heels of recently presented preclinical data validating the proof of concept for oxypurinol.
Dr. Davidoff spoke to us in-depth about the company he helms, and how they aim to combat progressive kidney disease.